Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down29.500 -0.150 (-0.506%)

15/09/2021 10:11

Livzon Pharma (01513) unit gets notice of acceptance

[ET Net News Agency, 15 September 2021] Livzon Pharmaceutical Group Inc. (01513) said
its subsidiary Livzon Group Xinbeijiang Pharmaceutical Manufacturing Inc. has recently
received the Notice of Acceptance (acceptance No: CXSL2101318 Guo) issued by China
National Medical Products Administration (NMPA). The application for the clinical trial of
a domestically manufactured drug, the Semaglutide Injection, was accepted by NMPA.
It is a novel and long-sustained glucagon-like peptide 1 (GLP-1) receptor agonist and is
used for the blood sugar control of adult patients with type 2 diabetes who has received,
on the basis of diet control and exercise, the treatment of metformin and/or sulfonylureas
but failed to control their blood sugar, and for reducing the risk of major adverse
cardiovascular events (such as cardiovascular death, non-fatal myocardial infarction, or
non-fatal stroke) in adult patients with type 2 diabetes as well as cardiovascular
diseases. (RC)

Remark: Real time quote last updated: 20/01/2022 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.